Changes in Hong Kong stocks | Weisheng Pharmaceutical-B (02561) rose more than 5%, and commercial sales of Weizhengo® are gradually increasing, and the company will achieve a steady transition to “product fulfillment”

The Zhitong Finance App learned that Weisheng Pharmaceutical-B (02561) rose more than 5% at the end of the session. As of press release, it had risen 5.13% to HK$20.08, with a turnover of HK$701,400.

^{According to the news, Weisheng Pharmaceutical's core product, Long-acting Growth Hormone Growth Hormone (trade name Weizhengo®), was officially approved for marketing. It is suitable for the treatment of growth hormone deficiency in children and adolescents aged 3 and above, which also means that Weisheng Pharmaceutical has begun a commercial implementation cycle.} According to Frost & Sullivan data, China's growth hormone market is expected to reach 28.6 billion yuan in 2030, with plenty of long-term growth momentum. In this incremental market, Weizhengao ^® is the first BIC product in China that also has the advantage of “long-term effective+natural structure”, and is expected to open up a space for differentiated competition in the high-end market.

The Zhitong Finance App points out in “Behind the nearly 30% intraday increase in Weisheng Pharmaceutical-B (02561): Market Focus on Core Product Volume, Further Acceleration of Commercialization of Weizheng®” that in 2026, Weisheng Pharmaceutical is commercializing through imports, and plans to achieve technology transfer and localized production in 2028. Currently, the company is cooperating with selected CDMO partner Pharmaceutical Biotech to promote localized production, further consolidating the company's manufacturing capabilities and competitive advantage in the supply chain. As Weizhenko ^®'s commercial sales gradually expand and contribute to performance revenue, the company will achieve a steady transition to “product fulfillment,” and its valuation center will also receive more solid fundamental support.